

# Staying In Sequence: Piecing Together the Puzzle of HR+/HER2- Metastatic Breast Cancer

## Pharmacy Grand Rounds 2026

5/21/26, 1200-1300 CST/1300-1400 EST

Aurora St. Lukes Medical Center Family Practice LL and Virtual Via Teams

**Overview:** This presentation will provide an evidence-based overview of treatment sequencing strategies for hormone receptor-positive, HER2-negative metastatic breast cancer. Will review subsequent line therapy options as well as targeted therapies, factors influencing therapy selection, and treatment sequencing principles to support optimal therapeutic decision-making across lines of treatment.

**Speaker:** Julianna Kuecker, PharmD – PGY2 Oncology Pharmacy Resident – Aurora Health Care Metro, Inc

**Preceptors:** Ellen Popov, PharmD, BCOP and Andy Ackerman, PharmD, BCOP

### **Objectives:**

1. Evaluate evidence-based sequencing strategies following progression for HR+/HER2- metastatic breast cancer, including subsequent treatment line options and targeted therapies.
2. Interpret key biomarkers and explain how they inform individualized therapy selection and sequencing decisions.
3. Identify mechanisms of resistance to targeted therapies and assess strategies to overcome or manage resistance in subsequent treatment lines.
4. Describe practical approaches to optimizing patient care, including toxicity management, drug–drug interaction mitigation, and supportive care considerations when sequencing targeted agents.

**Target Audience:** Advocate Health Pharmacists, Physicians, Nurses, and other interested healthcare professionals

**Disclosure:** The planner Alex Wolff was an advisory board member for Bristol Myers Squibb. The relationship ended 9/25/25. She was also an advisory board member for Syndax Pharmaceuticals. The relationship ended 4/9/25. She was also an advisory board member for Incyte Pharmaceuticals. The relationship ended 3/25/26. The other planner(s) and speaker(s) have indicated that there are no relevant financial relationships with any ineligible companies to disclose. All of the relevant financial relationships listed for Alex Wolff have been mitigated.

**Link to Live Sessions:** [Pharmacy Grand Rounds 2026](#)

**Commercial Support:** There is no financial support for this activity.

### **Accreditation Statement:**



In support of improving patient care, Advocate Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

### **Credit Statement(s):**

#### **Accreditation Council for Pharmacy Education (ACPE):**

Advocate Health designates this live activity for a maximum of 1 hour of CPE credit for pharmacists. CPE credit can be claimed on the AH CE platform within 60 days of activity completion and information will be provided to CPE Monitor. Participants should only claim credit commensurate with the extent of their participation in the activity.

**UAN:** JA0006327-0000-26-001-L01-P

**American Medical Association (AMA):** Advocate Health designates this live activity for a maximum of 1.0 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**American Nurses Credentialing Center (ANCC):** Advocate Health designates this live activity for a maximum of 1.0 ANCC contact hours/APRN pharmacological hours. Nurses should claim only the credit commensurate with

the extent of their participation in the activity.

Contact Elaine Thomas ([elaine.r.thomas@advocatehealth.org](mailto:elaine.r.thomas@advocatehealth.org)) with questions.

